psoriasis
FDA Expands Indication for Abatacept to Treat Juvenile Psoriatic Arthritis
The FDA expanded the indication for abatacept for the treatment of patients 24 months of age and older with active ...
NOVEMBER 3, 2023
FDA Approves First Steroid-Free Cream for Plaque Psoriasis
Vtama is an aryl hydrocarbon receptor agonist approved for adults with plaque psoriasis.
MAY 27, 2022
FDA Grants Second Indication for Skyrizi
The FDA granted a new indication for risankizumab-rzaa to treat adults with active psoriatic arthritis.
JANUARY 25, 2022
Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis
The FDA approved 15 mg of once-daily upadacitinib for the treatment of adults with active psoriatic arthritis who ...
DECEMBER 16, 2021
Despite Deadly Threat, Methotrexate Timing Mix-ups Still Happen
Mistakenly taking oral methotrexate daily instead of weekly can be deadly for patients who have rheumatoid ...
APRIL 17, 2020
Cimzia Receives New Indication for Moderate to Severe Plaque Psoriasis
The FDA approved a new indication for Cimzia to treat moderate to severe plaque psoriasis in adults.
JUNE 8, 2018
FDA Approves Siliq for Psoriasis
Psoriasis, an autoimmune disorder, occurs more commonly in patients with a family history of the disease, and most ...
FEBRUARY 17, 2017
FDA Approves Amjevita, a Biosimilar to Humira
The anti-inflammatory drug is the fourth biosimilar to be approved in the United States.
SEPTEMBER 29, 2016
ISMP Report Links Psoriasis Drugs and Cancer
Some biological products used to treat psoriasis may be associated with an increased risk for skin cancer and other ...
AUGUST 18, 2016
